Divi's Laboratories
DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com

Stock Price vs Company Growth
1d
0.3%
1w
2.4%
1m
4.4%
3m
11.6%
6m
3.8%
1y
50.7%
5y
21.2%
10y
22.2%
all
23.2%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

6,028 0.3%
4,942
6,307
Company Overview

Sales
9,078 Cr
Growth: 11.4%
Profit after Tax
2,067 Cr
Growth: 12.6%
Large Cap
1,60,035 Cr
P/E: 77.4x
Industry P/E: 31.8x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 9,078
Growth 11.4%
EBITDA 31.0%
P/S 17.6x
Dividend 0.6%
P/E 77.4x
Book Value ₹ 569
PEG Ratio 6.8x
ROE 14.5%
P/B 10.6x
Shareholding Pattern

Institutions
Sbi Mutual Fund
4.49 %
Qualified Institutional Buyer
3.57 %
Axis Mutual Fund Trustee Ltd
3.37 %
Government Pension Fund Global
1.29 %
Life Insurance Corporation Of India
1.15 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar22Sep22Mar24Sep24
Promoters
Nilima Prasad Divi
20.34 %
Divi Satchandra Kiran
20.34 %
Divi Swarna Latha
5.27 %
Divi'S Biotech Private Limited
3.01 %
Murali Krishna Prasad Divi
2.85 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar22Sep22Mar24Sep24
Others
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Mar22Sep22Mar24Sep24
Increase    Decrease    No change
Company Profile Detailed

The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.
Investors (131)
Followers (42)